Last reviewed · How we verify

CBD, synthetic form — Competitive Intelligence Brief

CBD, synthetic form (CBD, synthetic form) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Pain management, Anxiety disorders.

phase 2 CB1 and CB2 receptors Pain management, Anxiety disorders Small molecule Live · refreshed every 30 min

Target snapshot

CBD, synthetic form (CBD, synthetic form) — CannaMore Biotechs. CBD, a synthetic form, interacts with the body's endocannabinoid system to produce therapeutic effects.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CBD, synthetic form TARGET CBD, synthetic form CannaMore Biotechs phase 2 CB1 and CB2 receptors
medical cannabis medical cannabis HaEmek Medical Center, Israel phase 3 CB1 and CB2 receptors
THC/CBD THC/CBD Azienda Ospedaliera Universitaria Policlinico "G. Martino" phase 3 cannabinoid CB1 and CB2 receptors
Single-dose of cannabis oil Single-dose of cannabis oil Hadassah Medical Organization phase 3 CB1 and CB2 receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CBD, synthetic form — Competitive Intelligence Brief. https://druglandscape.com/ci/cbd-synthetic-form. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing